B.Riley Financial analyst Yuan Zhi reiterated a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report) today and set a price target of $18.00. The company's shares opened today at $14.47.According to TipRanks, Zhi is an analyst with an average return of -14.4% and a 26.32% success rate. Zhi covers the Healthcare sector, focusing on stocks such as IVERIC bio, Actinium Pharmaceuticals, and Azenta.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $30.00 average price target, which is a 107.33% upside from current levels. In a report released today, H.C.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-receives-a-buy-from-b-riley-financial?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals